Current Lab Members
Kyle Medley, MS
Kyle Medley’s research focuses on early discovery and development of small molecule, oral anti-cancer therapeutics that target the specific stress response kinase GCN2 and Trp–Asp repeat domain 5 (WDR5) MLL1 (Mixed Lineage leukemia) complex. Additionally, he is working on collaborative programs: KRAS, SWI/SNF complex targeting BRG1 and targeting/treating these pathways and mutations found in leukemia (AML, CML, and TLL), metastatic breast cancer, melanoma, and NSCLCs. Kyle’s education background includes an MS in chemical biology from the University of Michigan and a BS in biology, with a minor in chemistry, from Utah Valley University. When he’s not in lab, he enjoys golfing and being outdoors.
Dongqing Yan, PhD
Associate Research Scientist
Dongqing Yan, PhD, has a long-standing interest in the biology and therapies of cancers. She received her doctoral degree in pharmacology at SUNY Upstate Medical University and completed her postdoctoral training with Dr. Michael Deininger at Huntsman Cancer Institute, University of Utah. She joined the Hari Lab as a research scientist in May 2020 to continue pursuing her passionate interest in translational cancer research, especially in immuno-oncology.
While her graduate and postgraduate research has focused on identification and characterization of novel therapeutic targets in hematopoietic malignancies, current efforts are expanding the reach of her expertise to include solid tumors. She has authored 22 publications and received many prestigious awards including the Special Fellow Award from the Leukemia & Lymphoma Society and the International Award from the Lady Tata Trust of UK. In addition, she has presented her research five times at the American Society of Hematology Annual Meeting. Her projects in the Hari Lab include establishing multiple myeloma organoids from patient bone aspirates and testing and characterizing the molecular mechanisms of inhibitor actions.
Zhaoliang Li, PhD
Zhaoliang Li, PhD, is a postdoctoral fellow in the Hari Lab. He is working on small molecule heterocyclic compounds for drug discovery and drug development projects, including design, synthesis of novel chemical entities (NCE), and optimization of novel compounds, chemical scaffolds, and fragments. Dr. Li also specializes in analysis of NMR (1HNMR, 13CNMR, H, H-COSY, HSQC, and HMBC) and LC-MS data for small molecules. Prior to joining Huntsman Cancer Institute, Dr. Li was a postdoctoral fellow at Translational Genomics Research Institute (TGEN) from November 2017 to May 202. The TGEN team is focused on developing small molecules for cancer. Dr. Li received his PhD in medicinal chemistry from China Pharmaceutical University. His research focuses on computer aided drug discovery (CADD): virtual screening and optimization of lead compounds with goals to develop one or more candidates into clinical trials and save lives of cancer patients in the future.
Former Lab Members
Yugandhar Kothapalli, PhD
Postdoctoral Fellow (2020-2021)